Overview
The sevoflurane, isoflurane and desflurane market is expected to
reach USD 1.5 billion by 2022 in comparison to USD 1.2 billion in 2014.
These three chemicals are inhalation agents and have been used by
anesthesiologists, nurse anesthetists, and anesthesiology assistants on a
consistent basis. They are very strong and cost less, with minimum
damage to the ozone layer.
Browse Detail Report With TOC @ http://www.hexaresearch.com/research-report/sevoflurane-isoflurane-desflurane-industry/
Market Drivers
One of the primary factors, triggering expansion in the sevoflurane,
isoflurane and desflurane market includes cardiovascular and respiratory
diseases affecting the geriatric population. Rising cancer, orthopedic,
spinal and gastro-intestinal cases have also furthered the market.
Cataract surgery is a major contributor to the global market and will
need a higher production of these chemicals.
Growing accidents and emergency cases also add income to the
inhalation anesthesia market. Universal insurance coverage as well as
constant improvements in medical infrastructure also ensure the
development of the sevoflurane, isoflurane and desflurane market. These
agents are administered to patients prior surgery, making the induction
of general anesthesia much simpler.
A major factor hindering the market is the quantity of CO2 released
in the environment, leading to global warming. Actually, only about 5
percent of the gases are consumed by patients. The rest are released
into the atmosphere and make it unhealthy. The most practical solution
for this problem is the anesthetic recycling of products used during the
administration of general anesthesia.
Products Overview
Sevoflurane
Sevoflurane is one of the most commonly used volatile anesthetic
agents. It is administered to babies and children. Sevoflurane is ideal
for patients with asthma or sensitive air passages. But its side-effects
include delirium and agitation. It can be given quickly without the use
of intravenous instruments.
Sevoflurane would capture over 70% of the worldwide sevoflurane,
isoflurane and desflurane market by 2022. The agent is expected to
exceed USD 1 billion by the same year. It’s widely utilized for being
low-priced and possessing therapeutic benefits.
Request A Sample copy of This Report @ http://www.hexaresearch.com/sample/268
Isoflurane
Isoflurane is a halogen ether utilized frequently by veterinarians. It
is administered intravenously, relaxes the muscles and reduces pain.
Isoflurane has also been used for inducing sleepiness for long durations
during surgery. It is expected to register a CAGR of about 10% by 2022.
Desflurane
Desflurane is a halogen ether used in general anesthesia. Its
effectiveness is one-fifth of isoflurane. Desflurane cannot be
administered orally and requires an electrically heated dispenser to
distribute the vapor. It is mostly administered to bariatric patients
and in cases of surgeries lasting for short durations.
Regional Overview
The United States has a large geriatric population. This has led the
region of North America to occupy the biggest share in the worldwide
inhalation anesthesia market in 2014. Surgical ambulatory and inpatient
procedures are the driving factors of North America.
Asia Pacific will experience the fastest growth by 2022. This is
owing to the rise of chronic diseases and need for better health
infrastructure in the region. Medical tourism combined with insurance
coverage will play a huge role in sustaining the growth of the
sevoflurane, isoflurane and desflurane market.
Browse All Pharmaceuticals Industry Research Related Reports @http://www.hexaresearch.com/research-category/pharmaceuticals-industry/
Key Players
The market is currently dominated by AbbVie and Baxter International.
However, it can expect strong competition from manufacturers like
Lunan Pharmaceutical Group and Piramal Enterprises.
Piramal Enterprises currently has isoflurane and sevoflurane
production underway. It will manufacture generic desflurane by 2016.
AbbVie has sevoflurane and isoflurane under production. Baxter
International is the only one that manufactures all the three products.
Anesthesia has some unhealthy effects. The recycling companies of
Deltasorb Technologies and Anesthetic Gas Reclamation reprocess
anesthesia containers and gases from hospital vents. Rising investments
by the aforementioned players would also accelerate the sales of the
sevoflurane, isoflurane and desflurane market.
Browse Full Report @ http://www.hexaresearch.com/research-report/sevoflurane-isoflurane-desflurane-industry/
About Us:
Hexa Research is a market research and consulting organization,
offering industry reports, custom research and consulting services to a
host of key industries across the globe. We offer comprehensive business
intelligence in the form of industry reports which help our clients
obtain clarity about their business environment and enable them to
undertake strategic growth initiatives.
Contact Us:
Ryan Shaw
Hexa Research
Felton Office Plaza
6265 Highway 9
Felton, California 95018
United States
Phone: +1-800-489-3075
Email: sales@hexaresearch.com
Website - http://www.hexaresearch.com/
Visit our Blog: http://hexaresearchinc.blogspot.com/
No comments:
Post a Comment